Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age
Clinical trial NCT06546423 · COMPLETED
Trial details
- NCT number
- NCT06546423
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-12
- Primary completion
- 2025-06-04
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.